PT2902025T - Agente terapêutico para dislipidemia - Google Patents

Agente terapêutico para dislipidemia

Info

Publication number
PT2902025T
PT2902025T PT138423819T PT13842381T PT2902025T PT 2902025 T PT2902025 T PT 2902025T PT 138423819 T PT138423819 T PT 138423819T PT 13842381 T PT13842381 T PT 13842381T PT 2902025 T PT2902025 T PT 2902025T
Authority
PT
Portugal
Prior art keywords
dyslipidemia
therapeutic agent
therapeutic
agent
Prior art date
Application number
PT138423819T
Other languages
English (en)
Portuguese (pt)
Inventor
Takizawa Toshiaki
Yoshinaka Yasunobu
Original Assignee
Kowa Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kowa Co filed Critical Kowa Co
Publication of PT2902025T publication Critical patent/PT2902025T/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42Oxazoles
    • A61K31/423Oxazoles condensed with carbocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PT138423819T 2012-09-27 2013-09-27 Agente terapêutico para dislipidemia PT2902025T (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2012214635 2012-09-27

Publications (1)

Publication Number Publication Date
PT2902025T true PT2902025T (pt) 2019-11-04

Family

ID=50387566

Family Applications (1)

Application Number Title Priority Date Filing Date
PT138423819T PT2902025T (pt) 2012-09-27 2013-09-27 Agente terapêutico para dislipidemia

Country Status (20)

Country Link
US (4) US9572798B2 (enExample)
EP (1) EP2902025B1 (enExample)
JP (1) JP6238460B2 (enExample)
KR (1) KR102098032B1 (enExample)
CN (1) CN104640544B (enExample)
AU (1) AU2013321918B2 (enExample)
BR (1) BR112015006305B1 (enExample)
CA (1) CA2901650C (enExample)
EA (1) EA024873B1 (enExample)
ES (1) ES2752039T3 (enExample)
IL (1) IL237981B (enExample)
IN (1) IN2015DN02966A (enExample)
MX (1) MX357446B (enExample)
MY (1) MY177686A (enExample)
PH (1) PH12015500471A1 (enExample)
PL (1) PL2902025T3 (enExample)
PT (1) PT2902025T (enExample)
SG (1) SG11201501740XA (enExample)
TW (1) TWI598098B (enExample)
WO (1) WO2014050134A1 (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI691331B (zh) * 2014-09-26 2020-04-21 日商興和股份有限公司 脂質異常症治療劑
KR20200024165A (ko) * 2017-06-30 2020-03-06 교와 가부시키가이샤 의약 조성물
WO2019004448A1 (ja) * 2017-06-30 2019-01-03 興和株式会社 医薬組成物
JPWO2019004452A1 (ja) * 2017-06-30 2020-04-30 興和株式会社 医薬組成物
US11344535B2 (en) 2017-06-30 2022-05-31 Kowa Company, Ltd. Pharmaceutical composition
JPWO2019004453A1 (ja) * 2017-06-30 2020-04-30 興和株式会社 医薬品
HUE069648T2 (hu) * 2017-06-30 2025-03-28 Kowa Co Gyógyszerészeti készítmény
EP3646864B1 (en) 2017-06-30 2026-04-08 Kowa Company, Ltd. Pharmaceutical containing pemafibrate
JP7425603B2 (ja) * 2017-06-30 2024-01-31 興和株式会社 医薬組成物
US11446282B2 (en) 2017-12-21 2022-09-20 Kowa Company, Ltd. Methods of treating mixed dyslipidemia and hypertriglycertdemia
US20190224169A1 (en) * 2017-12-21 2019-07-25 Kowa Company, Ltd. Methods of Treatment of Hypertriglyceridemia
EP3903781A4 (en) * 2018-12-27 2023-01-25 Kowa Company, Ltd. PHARMACEUTICAL PREPARATION
US20220096443A1 (en) * 2018-12-27 2022-03-31 Kowa Company, Ltd. Pharmaceutical composition
JP2020105174A (ja) * 2018-12-27 2020-07-09 興和株式会社 医薬組成物

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU230253B1 (hu) 2001-01-26 2015-11-30 Merck Sharp & Dohme Corp Peroxiszóma proliferátor-aktivált receptor (PPAR) aktivátor(ok) és szterin-abszorpció inhibitor(ok) kombinációi és alkalmazásuk vaszkuláris indikációk kezelésére
US7205321B2 (en) 2001-11-15 2007-04-17 Eli Lilly And Company Peroxisome proliferator activated receptor alpha agonists
US6987118B2 (en) 2003-05-21 2006-01-17 Pfizer Inc. Tetrahydroisoquinoline derivatives as PPAR-alpha activators
WO2005009942A1 (ja) 2003-07-28 2005-02-03 Kyorin Pharmaceutical Co., Ltd. 光学活性置換フェニルプロピオン酸誘導体
EA009374B1 (ru) 2003-09-03 2007-12-28 Кова Ко., Лтд. Активирующее ppar соединение и содержащая его фармацевтическая композиция
CN100425594C (zh) * 2003-09-03 2008-10-15 兴和株式会社 Ppar活性化化合物及含该化合物的医药组合物
DE102004016845A1 (de) 2004-04-07 2005-10-27 Bayer Healthcare Ag Phenylthioessigsäure-Derivate und ihre Verwendung
US7629372B2 (en) 2004-09-16 2009-12-08 Merck & Co., Inc. Compounds for the treatment of dyslipidemia and other lipid disorders
TWI359810B (en) 2004-11-04 2012-03-11 Mitsubishi Tanabe Pharma Corp Carboxylic acid derivative containing thiazole rin
WO2007008529A2 (en) 2005-07-08 2007-01-18 Kalypsys, Inc Celullar cholesterol absorption modifiers
WO2007008541A2 (en) 2005-07-08 2007-01-18 Kalypsys, Inc. Cellular cholesterol absorption modifiers
US7795291B2 (en) 2006-07-07 2010-09-14 Bristol-Myers Squibb Company Substituted acid derivatives useful as anti-atherosclerotic, anti-dyslipidemic, anti-diabetic and anti-obesity agents and method
CA2663502A1 (en) 2006-09-15 2008-03-20 Schering Corporation Azetidinone derivatives and methods of use thereof
WO2008104875A1 (en) 2007-03-01 2008-09-04 Pfizer Products Inc. Oxazolidinones as cholesterol absorption inhibitors
TWI407955B (zh) * 2007-03-29 2013-09-11 Kowa Co 高脂血症之預防及/或治療劑
WO2009047240A1 (en) 2007-10-09 2009-04-16 Smithkline Beecham Corporation Indole derivatives useful as ppar activators
DE102007061757A1 (de) 2007-12-20 2009-06-25 Bayer Healthcare Ag Substituierte 2-Phenylpyrimidin-5-carbonsäuren und ihre Verwendung

Also Published As

Publication number Publication date
KR20150063035A (ko) 2015-06-08
AU2013321918B2 (en) 2018-05-10
PH12015500471B1 (en) 2015-04-20
EP2902025B1 (en) 2019-08-07
HK1206620A1 (zh) 2016-01-15
JP6238460B2 (ja) 2017-11-29
US9572798B2 (en) 2017-02-21
US20190167645A1 (en) 2019-06-06
EP2902025A4 (en) 2016-03-02
MX357446B (es) 2018-07-10
MX2015003705A (es) 2015-06-10
IL237981A0 (en) 2015-05-31
US20180185337A1 (en) 2018-07-05
EA024873B1 (ru) 2016-10-31
CA2901650C (en) 2021-05-04
CN104640544A (zh) 2015-05-20
US10258609B2 (en) 2019-04-16
CN104640544B (zh) 2017-05-03
US20150196538A1 (en) 2015-07-16
BR112015006305A2 (pt) 2017-07-04
BR112015006305B1 (pt) 2020-11-17
TW201417811A (zh) 2014-05-16
IL237981B (en) 2020-05-31
ES2752039T3 (es) 2020-04-02
EP2902025A1 (en) 2015-08-05
PL2902025T3 (pl) 2020-03-31
IN2015DN02966A (enExample) 2015-09-18
PH12015500471A1 (en) 2015-04-20
WO2014050134A1 (ja) 2014-04-03
US9931321B2 (en) 2018-04-03
TWI598098B (zh) 2017-09-11
KR102098032B1 (ko) 2020-04-07
US20170112811A1 (en) 2017-04-27
AU2013321918A1 (en) 2015-04-23
EA201590653A1 (ru) 2015-07-30
CA2901650A1 (en) 2014-04-03
SG11201501740XA (en) 2015-04-29
US11013722B2 (en) 2021-05-25
JPWO2014050134A1 (ja) 2016-08-22
MY177686A (en) 2020-09-23

Similar Documents

Publication Publication Date Title
GB201212513D0 (en) Therapeutic agents
IL233756A0 (en) New treatment factors
IL237981A0 (en) Medical material for excess lipids in the blood
EP2867209A4 (en) COMPOUNDS AND THEIR THERAPEUTIC USES
IL227558A0 (en) A therapeutic agent for tumors
GB201217439D0 (en) Combination therapy
SG11201405766SA (en) Methods for increasing efficacy of cd37-based therapy
ZA201406786B (en) Anti-malarial agents
GB201217704D0 (en) Therapeutic agents
PL2723330T3 (pl) Lek kombinowany zawierający środek naczynioskurczowy
ZA201408094B (en) Anti-malarial agents
GB201207305D0 (en) Therapy
ZA201504065B (en) Therapeutic agent for keratoconjunctive disorders
GB201420971D0 (en) Therapeutic composition
IL217807A0 (en) Therapeutic compositions
EP2804853A4 (en) THERAPEUTIC USES
ZA201601152B (en) Therapeutic agent for dyslipidemia
SG11201406911RA (en) Hair-growing agent
IL236873A0 (en) therapeutic compounds
GB201223021D0 (en) Therapeutic agents
GB201212512D0 (en) Therapeutic agents
GB201214985D0 (en) Modified therapeutic agents
GB201210233D0 (en) Therapeutic agents
GB201213712D0 (en) Modified therapeutic agents
ZA201405764B (en) Novel therapeutic agents